Literature DB >> 3132281

Nephrotic syndrome after treatment with 5-aminosalicylic acid.

B H Novis1, Z Korzets, P Chen, J Bernheim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3132281      PMCID： PMC2545896          DOI： 10.1136/bmj.296.6634.1442

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  3 in total

1.  5-aminosalicylic acid in serum and urine after administration by enema to patients with colitis.

Authors:  M J Dew; M Cardwell; N S Kidwai; B K Evans; J Rhodes
Journal:  J Pharm Pharmacol       Date:  1983-05       Impact factor: 3.765

2.  Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis.

Authors:  M J Dew; R E Ryder; N Evans; B K Evans; J Rhodes
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

3.  Nephrotic syndrome induced by tolmetin.

Authors:  G P Chatterjee
Journal:  JAMA       Date:  1981-10-02       Impact factor: 56.272
  3 in total
  22 in total

Review 1.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

Review 2.  Sulphasalazine in ulcerative colitis: in memoriam?

Authors:  J Hayllar; I Bjarnason
Journal:  Gut       Date:  1991-05       Impact factor: 23.059

3.  Nephrotic syndrome associated with sulphasalazine.

Authors:  V M Barbour; P F Williams
Journal:  BMJ       Date:  1990-10-06

Review 4.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

5.  Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.

Authors:  N Mahmud; D G Weir; D Kelleher
Journal:  Ir J Med Sci       Date:  1999 Oct-Dec       Impact factor: 1.568

6.  Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss.

Authors:  E A Masson; J M Rhodes
Journal:  Gut       Date:  1992-04       Impact factor: 23.059

Review 7.  Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.

Authors:  S B Hanauer; G Stathopoulos
Journal:  Drug Saf       Date:  1991 May-Jun       Impact factor: 5.606

8.  Evaluation of the physicochemical properties and dissolution characteristics of mesalamine: relevance to controlled intestinal drug delivery.

Authors:  D L French; J W Mauger
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

9.  Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children.

Authors:  L A Christensen; J Fallingborg; B A Jacobsen; K Abildgaard; H H Rasmussen; S N Rasmussen; S H Hansen
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

10.  Sulphasalazine induced renal failure.

Authors:  A D Dwarakanath; J Michael; R N Allan
Journal:  Gut       Date:  1992-07       Impact factor: 23.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.